ResearcherHarvard UniversityActive in the last 2 years

T.L. Correa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4524-6736; OpenAlex author ID A5017959764, A5141002834. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis. First author DOI 10.1016/j.esmoop.2026.107774 ↗
Association between ABO blood groups and pancreatic cancer outcomes: A systematic review and meta-analysis. Co-author DOI 10.1016/j.pan.2025.06.002 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Bruno Bockorny · 2 shared papers, 2025–2026 · strength 0.55
- Paper Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-… DOI 10.1016/j.esmoop.2026.107774 ↗
- Paper Association between ABO blood groups and pancreatic cancer outcomes: A systematic review and meta-analysis. DOI 10.1016/j.pan.2025.06.002 ↗
Mary Linton B. Peters · 1 shared paper, 2026 · strength 0.32
- Paper Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-… DOI 10.1016/j.esmoop.2026.107774 ↗
Seohyuk Lee · 1 shared paper, 2026 · strength 0.32
- Paper Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-… DOI 10.1016/j.esmoop.2026.107774 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.